Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


Articles published in Oncol Rep

Retrieve available abstracts of 84 articles:
HTML format
Text format



Single Articles


    February 2019
  1. ZOU M, Hu X, Xu B, Tong T, et al
    Glutathione Stransferase isozyme alpha 1 is predominantly involved in the cisplatin resistance of common types of solid cancer.
    Oncol Rep. 2019;41:989-998.
    PubMed     Text format     Abstract available


    January 2019
  2. WANG P, Zhang J, Xiong X, Yuan W, et al
    Icariin suppresses cell cycle transition and cell migration in ovarian cancer cells.
    Oncol Rep. 2019 Jan 28. doi: 10.3892/or.2019.6986.
    PubMed     Text format     Abstract available


  3. ALVES MR, Do Amaral NS, Marchi FA, Silva FIB, et al
    Prostaglandin D2 expression is prognostic in highgrade serous ovarian cancer.
    Oncol Rep. 2019 Jan 28. doi: 10.3892/or.2019.6984.
    PubMed     Text format     Abstract available


  4. WANG D, Xu Y, Feng L, Yin P, et al
    RGS5 decreases the proliferation of human ovarian carcinomaderived primary endothelial cells through the MAPK/ERK signaling pathway in hypoxia.
    Oncol Rep. 2019;41:165-177.
    PubMed     Text format     Abstract available


    December 2018
  5. WANG W, Wang J, Yan H, Zhang K, et al
    Upregulation of USP11 promotes epithelialtomesenchymal transition by deubiquitinating Snail in ovarian cancer.
    Oncol Rep. 2018 Dec 12. doi: 10.3892/or.2018.6924.
    PubMed     Text format     Abstract available


  6. LIU X, Hansen DM, Timko NJ, Zhu Z, et al
    Association between interleukin33 and ovarian cancer.
    Oncol Rep. 2018 Dec 7. doi: 10.3892/or.2018.6918.
    PubMed     Text format     Abstract available


  7. SHI J, Ye J, Fei H, Jiang SH, et al
    YWHAZ promotes ovarian cancer metastasis by modulating glycolysis.
    Oncol Rep. 2018 Dec 7. doi: 10.3892/or.2018.6920.
    PubMed     Text format     Abstract available


    November 2018
  8. MLYNSKA A, Salciuniene G, Zilionyte K, Garberyte S, et al
    Chemokine profiling in serum from patients with ovarian cancer reveals candidate biomarkers for recurrence and immune infiltration.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6886.
    PubMed     Text format     Abstract available


  9. LU DH, Yang J, Gao LK, Min J, et al
    Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelialmesenchymal transition.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6888.
    PubMed     Text format     Abstract available


  10. WANG X, Han L, Zhou L, Wang L, et al
    Prediction of candidate RNA signatures for recurrent ovarian cancer prognosis by the construction of an integrated competing endogenous RNA network.
    Oncol Rep. 2018;40:2659-2673.
    PubMed     Text format     Abstract available


    October 2018
  11. WANG W, Du H, Liu H, Hu F, et al
    SMAD specific E3 ubiquitin protein ligase 1 promotes ovarian cancer cell migration and invasion via the activation of the RhoA/ROCK signaling pathway.
    Oncol Rep. 2018 Oct 31. doi: 10.3892/or.2018.6836.
    PubMed     Text format     Abstract available


  12. HSU CY, Hsieh TH, Er TK, Chen HS, et al
    MiR381 regulates cell motility, growth and colony formation through PIK3CA in endometriosisassociated clear cell and endometrioid ovarian cancer.
    Oncol Rep. 2018 Oct 9. doi: 10.3892/or.2018.6779.
    PubMed     Text format     Abstract available


  13. ALSAMMAN K, El-Masry OS
    Staurosporine alleviates cisplatin chemoresistance in human cancer cell models by suppressing the induction of SQSTM1/p62.
    Oncol Rep. 2018;40:2157-2162.
    PubMed     Text format     Abstract available


    September 2018
  14. GUO H, Xu Y, Wang F, Shen Z, et al
    Clinical associations between ASCT2 and pmTOR in the pathogenesis and prognosis of epithelial ovarian cancer.
    Oncol Rep. 2018 Sep 24. doi: 10.3892/or.2018.6729.
    PubMed     Text format     Abstract available


  15. WANG YJ, Zheng LY, Wang ZF, Song R, et al
    Associations of genewide SNPs in SNAI1 and TWIST1 with breast cancer and ovarian cancer susceptibility among Chinese Han women.
    Oncol Rep. 2018 Sep 21. doi: 10.3892/or.2018.6725.
    PubMed     Text format     Abstract available


    August 2018
  16. XIANG J, Zhou L, Zhuang Y, Zhang J, et al
    Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by siSTAB1 in ovarian cancer.
    Oncol Rep. 2018 Aug 17. doi: 10.3892/or.2018.6658.
    PubMed     Text format     Abstract available


  17. LU YM, Wang Y, Liu SQ, Zhou MY, et al
    Profile and validation of dysregulated long noncoding RNAs and mRNAs in ovarian cancer.
    Oncol Rep. 2018 Aug 17. doi: 10.3892/or.2018.6654.
    PubMed     Text format     Abstract available


    July 2018
  18. SHISHIDO A, Mori S, Yokoyama Y, Hamada Y, et al
    Mesothelial cells facilitate cancer stemlike properties in spheroids of ovarian cancer cells.
    Oncol Rep. 2018 Jul 27. doi: 10.3892/or.2018.6605.
    PubMed     Text format     Abstract available


  19. MORIKAWA A, Hayashi T, Kobayashi M, Kato Y, et al
    Somatic copy number alterations have prognostic impact in patients with ovarian clear cell carcinoma.
    Oncol Rep. 2018;40:309-318.
    PubMed     Text format     Abstract available


  20. KAWAI Y, Shibata K, Sakata J, Suzuki S, et al
    KIF20A expression as a prognostic indicator and its possible involvement in the proliferation of ovarian clearcell carcinoma cells.
    Oncol Rep. 2018;40:195-205.
    PubMed     Text format     Abstract available


    June 2018
  21. YANG T, Cheng J, You J, Yan B, et al
    S100B promotes chemoresistance in ovarian cancer stem cells by regulating p53.
    Oncol Rep. 2018 Jun 27. doi: 10.3892/or.2018.6527.
    PubMed     Text format     Abstract available


  22. WEI Y, Han T, Wang R, Wei J, et al
    [Corrigendum] LSD1 negatively regulates autophagy through the mTOR signaling pathway in ovarian cancer cells.
    Oncol Rep. 2018 Jun 14. doi: 10.3892/or.2018.6495.
    PubMed     Text format     Abstract available


  23. SANCHEZ-CARRANZA JN, Diaz JF, Redondo-Horcajo M, Barasoain I, et al
    Gallic acid sensitizes paclitaxel-resistant human ovarian carcinoma cells through an increase in reactive oxygen species and subsequent downregulation of ERK activation.
    Oncol Rep. 2018;39:3007-3014.
    PubMed     Text format     Abstract available


    May 2018
  24. WEI Y, Han T, Wang R, Wei J, et al
    LSD1 negatively regulates autophagy through the mTOR signaling pathway in ovarian cancer cells.
    Oncol Rep. 2018 May 10. doi: 10.3892/or.2018.6432.
    PubMed     Text format     Abstract available


  25. WANG L, Zhang F, Cui JY, Chen L, et al
    CAFs enhance paclitaxel resistance by inducing EMT through the IL6/JAK2/STAT3 pathway.
    Oncol Rep. 2018;39:2081-2090.
    PubMed     Text format     Abstract available


    April 2018
  26. LIN Q, Guan W, Ren W, Zhang L, et al
    MALAT1 affects ovarian cancer cell behavior and patient survival.
    Oncol Rep. 2018 Apr 19. doi: 10.3892/or.2018.6384.
    PubMed     Text format     Abstract available


  27. ZHAN SJ, Liu B, Linghu H
    Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.
    Oncol Rep. 2018 Apr 19. doi: 10.3892/or.2018.6383.
    PubMed     Text format     Abstract available


  28. GARCIA-VAZQUEZ R, Gallardo Rincon D, Ruiz-Garcia E, Meneses Garcia A, et al
    let-7d-3p is associated with apoptosis and response to neoadjuvant chemotherapy in ovarian cancer.
    Oncol Rep. 2018 Apr 12. doi: 10.3892/or.2018.6366.
    PubMed     Text format     Abstract available


  29. CHEN Z, Zhu J, Zhu Y, Wang J, et al
    MicroRNA-616 promotes the progression of ovarian cancer by targeting TIMP2.
    Oncol Rep. 2018 Apr 12. doi: 10.3892/or.2018.6368.
    PubMed     Text format     Abstract available


    March 2018
  30. SONG K, Lv T, Chen Y, Diao Y, et al
    Emodin inhibits TGF-beta2 by activating the FOXD3/miR199a axis in ovarian cancer cells in vitro.
    Oncol Rep. 2018 Mar 6. doi: 10.3892/or.2018.6301.
    PubMed     Text format     Abstract available


  31. XU L, Xie Q, Qi L, Wang C, et al
    Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2+ signaling in SKOV3 cells.
    Oncol Rep. 2018;39:985-992.
    PubMed     Text format     Abstract available


    February 2018
  32. CUI Y, Wu F, Tian D, Wang T, et al
    miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8.
    Oncol Rep. 2018 Feb 12. doi: 10.3892/or.2018.6259.
    PubMed     Text format     Abstract available


  33. JANYST K, Janyst M, Siernicka M, Lasek W, et al
    Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells.
    Oncol Rep. 2018 Feb 6. doi: 10.3892/or.2018.6248.
    PubMed     Text format     Abstract available


  34. LIU L, Wang X, Li X, Wu X, et al
    Upregulation of IGF1 by tumor-associated macrophages promotes the proliferation and migration of epithelial ovarian cancer cells.
    Oncol Rep. 2018;39:818-826.
    PubMed     Text format     Abstract available


    January 2018
  35. ZHONG A, Zhang H, Xie S, Deng M, et al
    Inhibition of MUS81 improves the chemical sensitivity of olaparib by regulating MCM2 in epithelial ovarian cancer.
    Oncol Rep. 2018 Jan 22. doi: 10.3892/or.2018.6229.
    PubMed     Text format     Abstract available


  36. FUJIKAKE K, Kajiyama H, Yoshihara M, Nishino K, et al
    A novel mechanism of neovascularization in peritoneal dissemination via cancer-associated mesothelial cells affected by TGF-beta derived from ovarian cancer.
    Oncol Rep. 2018;39:193-200.
    PubMed     Text format     Abstract available


    December 2017
  37. HU H, Huang G, Wang H, Li X, et al
    Inhibition effect of triptolide on human epithelial ovarian cancer via adjusting cellular immunity and angiogenesis.
    Oncol Rep. 2017 Dec 15. doi: 10.3892/or.2017.6158.
    PubMed     Text format     Abstract available


  38. ZHANG N, Qiu J, Zheng T, Zhang X, et al
    Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway.
    Oncol Rep. 2017 Dec 15. doi: 10.3892/or.2017.6159.
    PubMed     Text format     Abstract available


  39. HAO Y, Zhu L, Yan L, Liu J, et al
    c-Fos mediates alpha1, 2-fucosyltransferase 1 and Lewis y expression in response to TGF-beta1 in ovarian cancer.
    Oncol Rep. 2017;38:3355-3366.
    PubMed     Text format     Abstract available


    October 2017
  40. XIE X, Yang M, Ding Y, Yu L, et al
    Formyl peptide receptor 2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer.
    Oncol Rep. 2017 Oct 13. doi: 10.3892/or.2017.6034.
    PubMed     Text format     Abstract available


    September 2017
  41. SU F, Geng J, Li X, Qiao C, et al
    SP1 promotes tumor angiogenesis and invasion by activating VEGF expression in an acquired trastuzumabresistant ovarian cancer model.
    Oncol Rep. 2017 Sep 25. doi: 10.3892/or.2017.5998.
    PubMed     Text format     Abstract available


  42. GAO J, Zhu H, Wan H, Zou X, et al
    Harmine suppresses the proliferation and migration of human ovarian cancer cells through inhibiting ERK/CREB pathway.
    Oncol Rep. 2017 Sep 13. doi: 10.3892/or.2017.5952.
    PubMed     Text format     Abstract available


  43. PARK GB, Kim D
    TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression.
    Oncol Rep. 2017 Sep 6. doi: 10.3892/or.2017.5941.
    PubMed     Text format     Abstract available


    August 2017
  44. JIA L, Zhou J, Zhao H, Jin H, et al
    Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snailglycolysis pathways.
    Oncol Rep. 2017 Aug 7. doi: 10.3892/or.2017.5886.
    PubMed     Text format     Abstract available


    July 2017
  45. ZHANG J, Liu L, Han S, Li Y, et al
    B7-H3 is related to tumor progression in ovarian cancer.
    Oncol Rep. 2017 Jul 31. doi: 10.3892/or.2017.5858.
    PubMed     Text format     Abstract available


  46. BAE JS, Lee J, Park Y, Park K, et al
    Attenuation of MUC4 potentiates the anticancer activity of auranofin via regulation of the Her2/Akt/FOXO3 pathway in ovarian cancer cells.
    Oncol Rep. 2017 Jul 28. doi: 10.3892/or.2017.5853.
    PubMed     Text format     Abstract available


  47. GUO X, Guo N, Zhao J, Cai Y, et al
    Active targeting co-delivery system based on hollow mesoporous silica nanoparticles for antitumor therapy in ovarian cancer stem-like cells.
    Oncol Rep. 2017 Jul 18. doi: 10.3892/or.2017.5829.
    PubMed     Text format     Abstract available


  48. LIU N, Peng SM, Zhan GX, Yu J, et al
    Human chorionic gonadotropin beta regulates epithelial-mesenchymal transition and metastasis in human ovarian cancer.
    Oncol Rep. 2017 Jul 14. doi: 10.3892/or.2017.5818.
    PubMed     Text format     Abstract available


  49. FENG D, Zhao T, Yan K, Liang H, et al
    Gonadotropins promote human ovarian cancer cell migration and invasion via a cyclooxygenase 2-dependent pathway.
    Oncol Rep. 2017 Jul 3. doi: 10.3892/or.2017.5784.
    PubMed     Text format     Abstract available


  50. QIU S, Sun L, Jin Y, An Q, et al
    Silencing of BAG3 promotes the sensitivity of ovarian cancer cells to cisplatin via inhibition of autophagy.
    Oncol Rep. 2017;38:309-316.
    PubMed     Text format     Abstract available


    June 2017
  51. FU X, Xu L, Qi L, Tian H, et al
    BMH-21 inhibits viability and induces apoptosis by p53-dependent nucleolar stress responses in SKOV3 ovarian cancer cells.
    Oncol Rep. 2017 Jun 23. doi: 10.3892/or.2017.5750.
    PubMed     Text format     Abstract available


  52. CHEN X, Ying X, Wang X, Wu X, et al
    Exosomes derived from hypoxic epithelial ovarian cancer deliver microRNA-940 to induce macrophage M2 polarization.
    Oncol Rep. 2017 Jun 6. doi: 10.3892/or.2017.5697.
    PubMed     Text format     Abstract available


    May 2017
  53. CAO S, Chen C, Xue J, Huang Y, et al
    Silencing of type Igamma phosphatidylinositol phosphate kinase suppresses ovarian cancer cell proliferation, migration and invasion.
    Oncol Rep. 2017 May 25. doi: 10.3892/or.2017.5670.
    PubMed     Text format     Abstract available


  54. SHAO G, Lai W, Wan X, Xue J, et al
    Inactivation of EGFR/AKT signaling enhances TSA-induced ovarian cancer cell differentiation.
    Oncol Rep. 2017;37:2891-2896.
    PubMed     Text format     Abstract available


  55. WINKLER I, Pyszniak M, Pogoda K, Semczuk A, et al
    Assessment of Th17 lymphocytes and cytokine IL17A in epithelial ovarian tumors.
    Oncol Rep. 2017;37:3107-3115.
    PubMed     Text format     Abstract available


  56. CHO SY, Kim K, Park MS, Jang MY, et al
    Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma.
    Oncol Rep. 2017;37:2620-2632.
    PubMed     Text format     Abstract available


    April 2017
  57. NAKAMURA K, Terai Y, Tanabe A, Ono YJ, et al
    CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
    Oncol Rep. 2017 Apr 19. doi: 10.3892/or.2017.5583.
    PubMed     Text format     Abstract available


  58. LIU Y, Li H, Ban Z, Nai M, et al
    Annexin A2 inhibition suppresses ovarian cancer progression via regulating beta-catenin/EMT.
    Oncol Rep. 2017 Apr 18. doi: 10.3892/or.2017.5578.
    PubMed     Text format     Abstract available


    March 2017
  59. GAO Y, Liu X, Li T, Wei L, et al
    Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer.
    Oncol Rep. 2017 Mar 27. doi: 10.3892/or.2017.5534.
    PubMed     Text format     Abstract available


  60. PARK GB, Chung YH, Kim D
    Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells.
    Oncol Rep. 2017 Mar 27. doi: 10.3892/or.2017.5533.
    PubMed     Text format     Abstract available


  61. LIU XX, Ye H, Wang P, Li LX, et al
    Proteomic-based identification of HSP70 as a tumor-associated antigen in ovarian cancer.
    Oncol Rep. 2017 Mar 24. doi: 10.3892/or.2017.5525.
    PubMed     Text format     Abstract available


  62. ZHANG Q, Chen WM, Zhang XX, Zhang HX, et al
    Overexpression of salusin-beta is associated with poor prognosis in ovarian cancer.
    Oncol Rep. 2017;37:1826-1832.
    PubMed     Text format     Abstract available


  63. YAN H, Qiu L, Xie X, Yang H, et al
    ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells.
    Oncol Rep. 2017;37:1412-1418.
    PubMed     Text format     Abstract available


  64. SATO M, Kawana K, Adachi K, Fujimoto A, et al
    Low uptake of fluorodeoxyglucose in positron emission tomography/computed tomography in ovarian clear cell carcinoma may reflect glutaminolysis of its cancer stem cell-like properties.
    Oncol Rep. 2017;37:1883-1888.
    PubMed     Text format     Abstract available


    January 2017
  65. GU G, Chen Y, Duan C, Zhou L, et al
    Overexpression of ARF1 is associated with cell proliferation and migration through PI3K signal pathway in ovarian cancer.
    Oncol Rep. 2017 Jan 18. doi: 10.3892/or.2017.5388.
    PubMed     Text format     Abstract available


  66. KIM BR, Kwon Y, Rho SB
    BMI-1 interacts with sMEK1 and inactivates sMEK1-induced apoptotic cell death.
    Oncol Rep. 2017;37:579-586.
    PubMed     Text format     Abstract available


    December 2016
  67. ZHANG H, Li W
    Dysregulation of micro-143-3p and BALBP1 contributes to the pathogenesis of the development of ovarian carcinoma.
    Oncol Rep. 2016;36:3605-3610.
    PubMed     Text format     Abstract available


    November 2016
  68. LONG Q, Yang R, Lu W, Zhu W, et al
    Adenovirus-mediated truncated Bid overexpression induced by the Cre/LoxP system promotes the cell apoptosis of CD133+ ovarian cancer stem cells.
    Oncol Rep. 2016 Nov 21. doi: 10.3892/or.2016.5263.
    PubMed     Text format     Abstract available


  69. SHEN Y, Zhang XY, Chen X, Fan LL, et al
    Synthetic paclitaxel-octreotide conjugate reverses the resistance of paclitaxel in A2780/Taxol ovarian cancer cell line.
    Oncol Rep. 2016 Nov 18. doi: 10.3892/or.2016.5260.
    PubMed     Text format     Abstract available


    October 2016
  70. YE J, Chen W, Wu ZY, Zhang JH, et al
    Upregulated CTHRC1 promotes human epithelial ovarian cancer invasion through activating EGFR signaling.
    Oncol Rep. 2016 Oct 24. doi: 10.3892/or.2016.5198.
    PubMed     Text format     Abstract available


  71. LI J, Huang H, Li Y, Li L, et al
    Decreased expression of long non-coding RNA GAS5 promotes cell proliferation, migration and invasion, and indicates a poor prognosis in ovarian cancer.
    Oncol Rep. 2016 Oct 24. doi: 10.3892/or.2016.5200.
    PubMed     Text format     Abstract available


  72. SANG XB, Sun KX, Wang LL, Chen S, et al
    Effects and mechanism of RhoC downregulation in suppressing ovarian cancer stem cell proliferation, drug resistance, invasion and metastasis.
    Oncol Rep. 2016 Oct 11. doi: 10.3892/or.2016.5164.
    PubMed     Text format     Abstract available


  73. GUO P, Xiong X, Zhang S, Peng D, et al
    miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
    Oncol Rep. 2016 Oct 3. doi: 10.3892/or.2016.5140.
    PubMed     Text format     Abstract available


    September 2016
  74. ZHU Q, Wu X, Wu Y, Wang X, et al
    Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer.
    Oncol Rep. 2016 Sep 28. doi: 10.3892/or.2016.5136.
    PubMed     Text format     Abstract available


  75. LU W, Lu T, Wei X
    Downregulation of DNMT3a expression increases miR-182-induced apoptosis of ovarian cancer through caspase-3 and caspase-9-mediated apoptosis and DNA damage response.
    Oncol Rep. 2016 Sep 28. doi: 10.3892/or.2016.5134.
    PubMed     Text format     Abstract available


  76. MENG Y, Hu J, Chen Y, Yu T, et al
    Silencing MARCH1 suppresses proliferation, migration and invasion of ovarian cancer SKOV3 cells via downregulation of NF-kappaB and Wnt/beta-catenin pathways.
    Oncol Rep. 2016 Sep 8. doi: 10.3892/or.2016.5076.
    PubMed     Text format     Abstract available


    June 2016
  77. MA K, Wang C, Geng Q, Fan Y, et al
    Recombinant adeno-associated virus-delivered anginex inhibits angiogenesis and growth of HUVECs by regulating the Akt, JNK and NF-kappaB signaling pathways.
    Oncol Rep. 2016;35:3505-13.
    PubMed     Text format     Abstract available


    April 2016
  78. DEVOR EJ, Schickling BM, Reyes HD, Warrier A, et al
    Cullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182.
    Oncol Rep. 2016;35:2461-5.
    PubMed     Text format     Abstract available


  79. ELSNEROVA K, Mohelnikova-Duchonova B, Cerovska E, Ehrlichova M, et al
    Gene expression of membrane transporters: Importance for prognosis and progression of ovarian carcinoma.
    Oncol Rep. 2016;35:2159-70.
    PubMed     Text format     Abstract available


    March 2016
  80. YANG M, Xie X, Ding Y
    SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
    Oncol Rep. 2016;35:1796-806.
    PubMed     Text format     Abstract available


    February 2016
  81. WENG Z, Gao H, Hu J, Fan Y, et al
    Isoalantolactone induces autophagic cell death in SKOV(3) human ovarian carcinoma cells via upregulation of PEA-15.
    Oncol Rep. 2016;35:833-40.
    PubMed     Text format     Abstract available


  82. TAKEDA T, Banno K, Okawa R, Yanokura M, et al
    ARID1A gene mutation in ovarian and endometrial cancers (Review).
    Oncol Rep. 2016;35:607-13.
    PubMed     Text format     Abstract available


  83. ZOU Y, Deng W, Wang F, Yu XH, et al
    A novel somatic MAPK1 mutation in primary ovarian mixed germ cell tumors.
    Oncol Rep. 2016;35:725-30.
    PubMed     Text format     Abstract available


  84. KIM BR, Lee SH, Park MS, Seo SH, et al
    MARCKSL1 exhibits anti-angiogenic effects through suppression of VEGFR-2-dependent Akt/PDK-1/mTOR phosphorylation.
    Oncol Rep. 2016;35:1041-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: